| |
|
|
|
Centro Congressi Giovanni XXIII, Bergamo, Italy
05 - 07 November 2018
The conference will update you on advances in targeted and immunological therapies. It will cover issues of diagnosis and early detection and the emergence, and role of, drug-tolerant tumour fractions. There will also be a focus on rational design of combinatorial therapies and on how advances emerging from the laboratory are clinically implemented. Andrea Califano (Columbia University) and David Solit (MSKCC) will give keynote lectures. Who should attend? Basic, translational and clinical faculty, postdocs and PhD students/trainees who are interested in currently pressing cancer-relevant questions and want to hear about the latest developments in therapies targeting cancer and immune cells. In addition, industry scientists interested in targets for novel therapies are encouraged to sign up. It is an excellent format for informal networking.
|
|
|
|
|
|
|
|
Organized by:
|
|
European Association for Cancer Research |
|
|
Invited Speakers:
|
|
Alberto Bardelli (Italy), Andrea Califano (USA), Silvia Formenti (USA), Johanna Joyce (Switzerland), Christoph Klein (Germany), Richard Marais (UK), Jean-Christophe Marine (Belgium), Fatima Mechta-Grigoriou (France), Daniel Peeper (Netherlands), Ze'ev Ronai (Israel), Eytan Ruppin (USA), Shai Shen-Orr (Israel), Maria Soengas (Spain), David Solit (USA), Inge Marie Svane (Denmark), Itay Tirosh (Israel)
|
|
|
|
|
|
|
|
Deadline for Abstracts:
|
|
03 September 2018
|
|
|
|
|
|
|
|
Registration:
|
|
Deadline: 01 October 2018
|
|
|
E-mail:
|
|
roger.doxat-pratt@nottingham.ac.uk
|
|
|
|
|
|
|
|
|